SEARCH

SEARCH BY CITATION

References

  • 1
    Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:6567.
  • 2
    Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848848.
  • 3
    Ellis TM, Simms PE, Slivnick DJ, Jäck H-M, Fisher RI. CD30 is a signal transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993;151:23802389.
  • 4
    Nawrocki J, Kirstein E, Fisher R. Biochemical and structural properties of a Hodgkin's disease related mem-brane protein. J Immunol 1988;141:672680.
  • 5
    Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421427.
  • 6
    Josimovic-Alasevic O, Durkop H, Schwarting R, Backé E, Stein H, Diamantstein T. KI-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989;19:157162.
  • 7
    Hansen HP, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995;63:750756.
  • 8
    Bengtsson Å, Scheynius A, Avila-Cariño J. Crosslinking of CD30 on activated human Th clones enhances their cytokine production and downregulates the CD30 expression. Scand J Immunol 2000;52:595601.DOI: 10.1046/j.1365-3083.2000.00830.x
  • 9
    Horn-Lohrens O, Tiemann M, Lange H, et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995;60:539544.
  • 10
    Gruss H-J, Pinto A, Duyster J, Poppema S, Herrman F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156163.DOI: 10.1016/s0167-5699(97)84661-0
  • 11
    Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994;12:793797.
  • 12
    Pizzolo G, Vinante F, Morosato L, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994;8:741745.
  • 13
    Smith C, Gruss H, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:13491360.
  • 14
    Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994;83:20452956.
  • 15
    Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant B lymphocytes. Br J Haematol 1996;93:569571.
  • 16
    Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30L and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996;88:32993305.
  • 17
    Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997;89:20482059.
  • 18
    Lee S, Park C, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996;183:669674.
  • 19
    Romagnani P, Annunziato F, Manetti R, et al. High CD30 ligand expression by epithelial cells and Hassall's corpuscles in the medulla of human thymus. Blood 1998;91:33233332.
  • 20
    Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996;84:551562.
  • 21
    Sverremark Ekström E, Bengtsson Å, Svensson A, et al. Presence of CD30+ and CD30L+ cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy. Placenta 2001 (in press).
  • 22
    Castelucci M & Kaufmann P. Hofbauer cells. In: BenirschkeK, KaufmannP, editors. Pathology of the human placenta. New York: Springer, 1992:7177.
  • 23
    Mallet V, Blaschitz A, Crisa L, et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83+ dendritic cells express HLA-G as a membrane-bound and soluble protein. Int Immunol 1999;11:889898.DOI: 10.1093/intimm/11.6.889
  • 24
    Mori M, Manuelli C, Pimpinelli N, et al. CD30–CD30 ligand interaction in primary cutaneous CD30+ T-cell lymphomas: a clue to the patho-physiology of clinical regression. Blood 1999;94:3077.
  • 25
    Agrawal B, Reddish M, Longenecker B. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes from normal donors. J Immunol 1996;157:32293234.
  • 26
    Gerdes J, Schwarting R, Stein H. High proliferative activity of Reed-Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol 1986;39:993997.
  • 27
    Shanebeck K, Maliszewski C, Kennedy M, et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995;25:21472153.
  • 28
    Cambiaggi A, Cantoni C, Marciano S, et al. Cultured human NK cells express the Ki-1/CD30 antigen. Br J Haematol 1993;85:270276.
  • 29
    Rudolph P, Lappe T, Schmidt D. Expression of CD30 and nerve growth factor in neoplastic and reactive vascular lesions: an immuno-histochemical study. Histopathology 1993;23:173178.
  • 30
    Ito K, Watanabe T, Horie R, Shiota M, Kawamura S, Mori S. High expression of the CD30 molecule in human decidual cells. Am J Pathol 1994;145:276.
  • 31
    Bengtsson Å, Holm L, Bäck O, Fransson J, Scheynius A. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 1997;109:533537.
  • 32
    Latza U, Davis S, Wilhelm D, McKnight B, Seyfarth M, Stein H. Soluble cytokine receptor CD30 in atopic disorders: a case-control study. Clin Exp Allergy 1999;29:97104.DOI: 10.1046/j.1365-2222.1999.00450.x
  • 33
    Abbondanzo S, Sato N, Straus S, Jaffe E. Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol 1990;93:698702.
  • 34
    Latza U, Foss H, Durkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 1995;146:463471.
  • 35
    Ferreiro J. Ber-H2 expression in testicular germ cell tumors. Hum Pathol 1994;25:522524.
  • 36
    Hittmair A, Rogatasch H, Hobisch A, Mikuz G, Feichtinger H. CD30 expression in seminoma. Hum Pathol 1996;27:11661171.
  • 37
    Fattovich G, Vinante F, Giustina G, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996;103:105110.
  • 38
    Woitas R, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997;159:10121018.
  • 39
    Vinante F, KramperA M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFNγ, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999;84:683689.
  • 40
    Reiner S & Seder R. T helper cell differentiation in immune response. Curr Opin Immunol 1995;7:360366.
  • 41
    Mossman T & Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;171:3846.
  • 42
    Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787793.
  • 43
    Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227257.
  • 44
    Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225235.DOI: 10.1006/clin.1996.0118
  • 45
    Kapsenberg M, Wierenga E, Bos J, Jansen H. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991;12:392395.
  • 46
    Rohowsky-Kochan C, Molinaro D, Cook S. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Multiple Sclerosis 2000;6:6977.
  • 47
    Miossec P. Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol 2000;12:181185.DOI: 10.1006/brbi.1998.0527
  • 48
    Piccinni M, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual cells in unexplained recurrent abortions. Nat Med 1998;4:10201024.DOI: 10.1038/2006
  • 49
    Romagnani S & Maggi E. Th1 versus Th2 responses in AIDS. Curr Opin Immunol 1994;6:616622.
  • 50
    Chilosi M, Facchetti F, Notarangelo L, et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol 1996;26:329334.
  • 51
    Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997;18:478482.DOI: 10.1016/s0167-5699(97)01127-4
  • 52
    Alzona M, Jäck H-M, Fisher R, Ellis T. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994;153:28612867.
  • 53
    Bengtsson Å, Johansson C, Tengvall Linder M, Halldén G, Van Der Ploeg I, Scheynius A. Not only Th2 but also Th1 and Th0 cells express CD30 after activation. J Leukoc Biol 1995;58:683689.
  • 54
    Romagnani S, Del Prete G, Maggi E, Chilosi M, Calgaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995;57:726730.
  • 55
    Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:8186.
  • 56
    Hamann D, Hilkens CM, Grogan JL, et al. CD30 expression does not discriminate between human Th1- and Th2-type cells. J Immunol 1996;156:13871391.
  • 57
    D'Elios M, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997;61:539544.
  • 58
    Clerici M & Shearer GM. A Th1[RIGHTWARDS ARROW]Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107111.
  • 59
    Maggi E, Annunziato F, Manetti R, et al. Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals. Immunity 1995;3:251255.
  • 60
    Nakamura Y, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol 1997;158:20902098.
  • 61
    Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998;160:21802187.
  • 62
    Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999;103:125138.
  • 63
    Rajka G. Essential aspects of atopic dermatitis. Berlin: Springer-Verlag, 1989.
  • 64
    Leung D. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860876.
  • 65
    Hanifin J & Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92:4447.
  • 66
    Leung D. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic disease. J Allergy Clin Immunol 1995;96:302319.
  • 67
    Kimura M, Tsuruta S, Yoshida T. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J Allergy Clin Immunol 1998;101:8489.
  • 68
    Hanifin J & Tofte S. Update on therapy of atopic dermatitis. J Allergy Clin Immunol 1999;104:123125.
  • 69
    Dummer W, Brocker EB, Bastian BC. Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. Br J Dermatol 1997;137:185187.
  • 70
    Caproni M, Bianchi B, D'Elios M, De Carli M, Amedi A, Fabbri P. In vivo relevance of CD30 in atopic dermatitis. Allergy 1997;52:10631070.
  • 71
    Frezzolini A, Paradisi M, Ruffelli M, Cadoni S, Depita O. Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997;52:106109.
  • 72
    Cavagni G, Caffarelli C, Facchetti F. Cutaneous CD30+ cells in children with atopic dermatitis. Int Arch Allergy Immunol 2000;121:224228.
  • 73
    Nickoloff B. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:11041110.
  • 74
    Dummer W, Rose C, Bröcker E-B. Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis, but not of allergic contact dermatitis. Arch Dermatol Res 1998;290:598602.DOI: 10.1007/s004030050358
  • 75
    Grewe M, Bruijnzeel-Koomen C, Schöpf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359361.DOI: 10.1016/s0167-5699(98)01285-7
  • 76
    Piletta P, Wirth S, Hommel L, Saurat J, Hauser C. Circulating skin-homing T cells in atopic dermatitis. Arch Dermatol 1996;132:11711176.
  • 77
    Leonard C, Tormey V, Faul J, Burke C, Poulter L. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997;27:780786.
  • 78
    Yamamoto J, Adachi Y, Onoue Y, et al. CD30 expression on circulating memory CD4+ T cells as a Th2- dominated situation in patients with atopic dermatitis. Allergy 2000;55:10111018.DOI: 10.1034/j.1398-9995.2000.00685.x
  • 79
    Esnault S, Benbernou N, Lavaud F, Guenounou M. Spontaneous CD30 mRNA expression in peripheral blood mononuclear cells from atopic patients with high IgE serum levels. Clin Exp Immunol 1996;106:6772.
  • 80
    Blanco Quirós A, Arranz E, Hoyos C, Gómez Carrasco J, Andión R. Different serum interleukin-12 and sCD30 levels in food- and pollen-sensitized children. Pediatr Allergy Immunol 1999;10:235240.DOI: 10.1034/j.1399-3038.1999.00039.x
  • 81
    Spinozzi F, Agea E, Bistoni O, et al. Local expansion of allergen-specific CD30+ Th2-type γδ T cells in bronchial asthma. Mol Med 1995;1:821826.
  • 82
    Suzuki H, Goto S, Ikeda K, Oshima T, Furukawa M, Takasaka T. IL-12 receptor β2 and CD30 expression in paranasal sinus mucosa of patients with chronic sinusitis. Eur Respir J 1999;13:10081013.
  • 83
    European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:2331.
  • 84
    Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189198.
  • 85
    Bäck O, Scheynius A, Johansson S. Ketaconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995;287:448451.
  • 86
    Holm L, Bengtsson Å, Öhman S, Van Hage-Hamsten M, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis. Allergy 2001;56:152158.
  • 87
    Bottari V, Frezzolini A, Ruffelli M, Puddu P, Fontana L, De Pità O. Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999;55:507510.
  • 88
    Caproni M, Salvatore E, Cardinali C, Brazzini B, Fabbri P. Soluble CD30 and cyclosporine in severe atopic dermatitis. Int Arch Allergy Immunol 2000;121:324328.
  • 89
    Piletta PA, Wirth S, Hommel L, Saurat JH, Hauser C. Circulating skin-homing T cells in atopic dermatitis. Arch Dermatol 1996;132:11711176.
  • 90
    Øymar K, L.ardal Å, Bjerknes R. Soluble CD30 and CD23 in cord blood are not related to atopy in early childhood. Pediatr Allergy Immunol 2000;11:220224.DOI: 10.1034/j.1399-3038.2000.00094.x
  • 91
    Lin H, Mossman T, Guilbert L, Tuntipopipat S, Wegmann T. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993;151:45624573.
  • 92
    Roth I, Corry D, Locksley R, Abrams J, Litton M, Fisher S. Human placental cytotrophoblasts produce immunosuppressive cytokine interleukin 10. J Exp Med 1996;184:539548.
  • 93
    Piccini M, Giudizi M, Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol 1995;155:128133.
  • 94
    Kelly R, Carr G, Eliott C, Tulppala M, Critchley H. Prostaglandin and cytokine release by trophoblastic villi. Hum Reprod 1995;10:3289.
  • 95
    Krampera M, Vinante F, Tavecchia L, et al. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999;117:291297.DOI: 10.1046/j.1365-2249.1999.00977.x
  • 96
    Makhseed M, Raghupathy R, Azizieh F, Farhat R, Hassan N, Bandar A. Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000;15:20112017.DOI: 10.1093/humrep/15.9.2011
  • 97
    Herbein G & O'Brien W. Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesis. Exp Biol Med 2000;223:241.
  • 98
    Smith C, Farrah T, Goodwin R. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994;76:959962.
  • 99
    Del Prete G, De Carli M, D'Elios MM, et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995;182:16551661.
  • 100
    Ducket CS & Thompson CB. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997;11:28102821.
  • 101
    Mavalia C, Scaletti C, Romagnani P. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:17511758.
  • 102
    Caligaris-Cappio F, Bertero M, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339343.
  • 103
    Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997;15:33553362.
  • 104
    Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 1995;2:587596.
  • 105
    Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000;105:399408.
  • 106
    International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998;351:12251232.DOI: 10.1016/s0140-6736(97)07302-9
  • 107
    Katoh N, Hirano S, Suehiro M, et al. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 2000;121:187192.DOI: 10.1046/j.1365-2249.2000.01286.x